Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umeclidinium Added to ICS/LABA in COPD
NCT02257372Phase 4Completed
- Sponsor
- GSK
- Start
- Sep 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 4 trial of umeclidinium in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Sep 2014; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02257372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257372.